114 related articles for article (PubMed ID: 8683875)
21. Triple-head SPECT with 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG): initial evaluation in oncology and comparison with FDG PET.
Macfarlane DJ; Cotton L; Ackermann RJ; Minn H; Ficaro EP; Shreve PD; Wahl RL
Radiology; 1995 Feb; 194(2):425-9. PubMed ID: 7824722
[TBL] [Abstract][Full Text] [Related]
22. Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients.
Schöder H; Erdi YE; Chao K; Gonen M; Larson SM; Yeung HW
J Nucl Med; 2004 Apr; 45(4):559-66. PubMed ID: 15073250
[TBL] [Abstract][Full Text] [Related]
23. PET FDG studies in oncology.
Hawkins RA; Hoh CK
Nucl Med Biol; 1994 Jul; 21(5):739-47. PubMed ID: 9241650
[TBL] [Abstract][Full Text] [Related]
24. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose in the imaging of malignant melanoma.
Gritters LS; Francis IR; Zasadny KR; Wahl RL
J Nucl Med; 1993 Sep; 34(9):1420-7. PubMed ID: 8355058
[TBL] [Abstract][Full Text] [Related]
25. Comparison of fluorine-18-FDG PET and thallium-201 SPECT in evaluation of lung cancer.
Higashi K; Nishikawa T; Seki H; Oguchi M; Nambu Y; Ueda Y; Yuasa K; Tonami H; Okimura T; Yamamoto I
J Nucl Med; 1998 Jan; 39(1):9-15. PubMed ID: 9443730
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the performance of a whole-body positron imaging system with attenuation correction.
Ota T; Ito K; Tadokoro M; Kato T; Nishino M; Amano M; Ishigaki T
Radiat Med; 1995; 13(3):121-8. PubMed ID: 7569003
[TBL] [Abstract][Full Text] [Related]
27. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose.
Steinert HC; Huch Böni RA; Buck A; Böni R; Berthold T; Marincek B; Burg G; von Schulthess GK
Radiology; 1995 Jun; 195(3):705-9. PubMed ID: 7753998
[TBL] [Abstract][Full Text] [Related]
28. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma.
Hoh CK; Glaspy J; Rosen P; Dahlbom M; Lee SJ; Kunkel L; Hawkin RA; Maddahi J; Phelps ME
J Nucl Med; 1997 Mar; 38(3):343-8. PubMed ID: 9074514
[TBL] [Abstract][Full Text] [Related]
29. Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations.
Engel H; Steinert H; Buck A; Berthold T; Huch Böni RA; von Schulthess GK
J Nucl Med; 1996 Mar; 37(3):441-6. PubMed ID: 8772641
[TBL] [Abstract][Full Text] [Related]
30. Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer.
Yen RF; Sun SS; Shen YY; Changlai SP; Kao A
Anticancer Res; 2001; 21(5):3691-4. PubMed ID: 11848544
[TBL] [Abstract][Full Text] [Related]
31. Application of whole-body positron emission tomography in the imaging of esophageal cancer: report of a case.
Yasuda S; Raja S; Hubner KF
Surg Today; 1995; 25(3):261-4. PubMed ID: 7640457
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of FDG PET in patients with cervical cancer.
Sugawara Y; Eisbruch A; Kosuda S; Recker BE; Kison PV; Wahl RL
J Nucl Med; 1999 Jul; 40(7):1125-31. PubMed ID: 10405131
[TBL] [Abstract][Full Text] [Related]
33. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose.
Shreve PD; Grossman HB; Gross MD; Wahl RL
Radiology; 1996 Jun; 199(3):751-6. PubMed ID: 8638000
[TBL] [Abstract][Full Text] [Related]
34. Breast imaging with fluorine-18-FDG PET: quantitative image analysis.
Avril N; Bense S; Ziegler SI; Dose J; Weber W; Laubenbacher C; Römer W; Jänicke F; Schwaiger M
J Nucl Med; 1997 Aug; 38(8):1186-91. PubMed ID: 9255146
[TBL] [Abstract][Full Text] [Related]
35. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation.
Stollfuss JC; Glatting G; Friess H; Kocher F; Berger HG; Reske SN
Radiology; 1995 May; 195(2):339-44. PubMed ID: 7724750
[TBL] [Abstract][Full Text] [Related]
36. Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma.
Bender H; Kirst J; Palmedo H; Schomburg A; Wagner U; Ruhlmann J; Biersack HJ
Anticancer Res; 1997; 17(3B):1687-92. PubMed ID: 9179219
[TBL] [Abstract][Full Text] [Related]
37. Parametric images of myocardial metabolic rate of glucose generated from dynamic cardiac PET and 2-[18F]fluoro-2-deoxy-d-glucose studies.
Choi Y; Hawkins RA; Huang SC; Gambhir SS; Brunken RC; Phelps ME; Schelbert HR
J Nucl Med; 1991 Apr; 32(4):733-8. PubMed ID: 2013815
[TBL] [Abstract][Full Text] [Related]
38. Neoplasms in a pediatric population: 2-[F-18]-fluoro-2-deoxy-D-glucose PET studies.
Shulkin BL; Mitchell DS; Ungar DR; Prakash D; Dole MG; Castle VP; Hernandez RJ; Koeppe RA; Hutchinson RJ
Radiology; 1995 Feb; 194(2):495-500. PubMed ID: 7824731
[TBL] [Abstract][Full Text] [Related]
39. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
Schaefferkoetter JD; Carlson ER; Heidel RE
J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
[TBL] [Abstract][Full Text] [Related]
40. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma.
Moon DH; Maddahi J; Silverman DH; Glaspy JA; Phelps ME; Hoh CK
J Nucl Med; 1998 Mar; 39(3):431-5. PubMed ID: 9529287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
